73 related articles for article (PubMed ID: 17230517)
21. Pediatric diffuse intrinsic pontine glioma: can optimism replace pessimism?
Hargrave D
CNS Oncol; 2012 Nov; 1(2):137-48. PubMed ID: 25057864
[TBL] [Abstract][Full Text] [Related]
22. Targeting of histone deacetylases in brain tumors.
Ecker J; Witt O; Milde T
CNS Oncol; 2013 Jul; 2(4):359-76. PubMed ID: 25054580
[TBL] [Abstract][Full Text] [Related]
23. The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells.
Kerl K; Ries D; Unland R; Borchert C; Moreno N; Hasselblatt M; Jürgens H; Kool M; Görlich D; Eveslage M; Jung M; Meisterernst M; Frühwald M
BMC Cancer; 2013 Jun; 13():286. PubMed ID: 23764045
[TBL] [Abstract][Full Text] [Related]
24. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study.
Hummel TR; Wagner L; Ahern C; Fouladi M; Reid JM; McGovern RM; Ames MM; Gilbertson RJ; Horton T; Ingle AM; Weigel B; Blaney SM
Pediatr Blood Cancer; 2013 Sep; 60(9):1452-7. PubMed ID: 23554030
[TBL] [Abstract][Full Text] [Related]
25. The histone deacetylase inhibitor sodium butyrate promotes cell death and differentiation and reduces neurosphere formation in human medulloblastoma cells.
Nör C; Sassi FA; de Farias CB; Schwartsmann G; Abujamra AL; Lenz G; Brunetto AL; Roesler R
Mol Neurobiol; 2013 Dec; 48(3):533-43. PubMed ID: 23516101
[TBL] [Abstract][Full Text] [Related]
26. Pediatric rhabdoid tumors of kidney and brain show many differences in gene expression but share dysregulation of cell cycle and epigenetic effector genes.
Birks DK; Donson AM; Patel PR; Sufit A; Algar EM; Dunham C; Kleinschmidt-DeMasters BK; Handler MH; Vibhakar R; Foreman NK
Pediatr Blood Cancer; 2013 Jul; 60(7):1095-102. PubMed ID: 23382118
[TBL] [Abstract][Full Text] [Related]
27. Valproic acid reduces the tolerability of temsirolimus in children and adolescents with solid tumors.
Coulter DW; Walko C; Patel J; Moats-Staats BM; McFadden A; Smith SV; Khan WA; Bridges AS; Deal AM; Oesterheld J; Davis IJ; Blatt J
Anticancer Drugs; 2013 Apr; 24(4):415-21. PubMed ID: 23328074
[TBL] [Abstract][Full Text] [Related]
28. Selective histonedeacetylase inhibitor M344 intervenes in HIV-1 latency through increasing histone acetylation and activation of NF-kappaB.
Ying H; Zhang Y; Zhou X; Qu X; Wang P; Liu S; Lu D; Zhu H
PLoS One; 2012; 7(11):e48832. PubMed ID: 23166597
[TBL] [Abstract][Full Text] [Related]
29. Deregulated chromatin remodeling in the pathobiology of brain tumors.
Spyropoulou A; Piperi C; Adamopoulos C; Papavassiliou AG
Neuromolecular Med; 2013 Mar; 15(1):1-24. PubMed ID: 23114751
[TBL] [Abstract][Full Text] [Related]
30. HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.
Milde T; Lodrini M; Savelyeva L; Korshunov A; Kool M; Brueckner LM; Antunes AS; Oehme I; Pekrun A; Pfister SM; Kulozik AE; Witt O; Deubzer HE
J Neurooncol; 2012 Dec; 110(3):335-48. PubMed ID: 23054560
[TBL] [Abstract][Full Text] [Related]
31. Acetylation Increases EWS-FLI1 DNA Binding and Transcriptional Activity.
Schlottmann S; Erkizan HV; Barber-Rotenberg JS; Knights C; Cheema A; Uren A; Avantaggiati ML; Toretsky JA
Front Oncol; 2012; 2():107. PubMed ID: 22973553
[TBL] [Abstract][Full Text] [Related]
32. REST is a novel prognostic factor and therapeutic target for medulloblastoma.
Taylor P; Fangusaro J; Rajaram V; Goldman S; Helenowski IB; MacDonald T; Hasselblatt M; Riedemann L; Laureano A; Cooper L; Gopalakrishnan V
Mol Cancer Ther; 2012 Aug; 11(8):1713-1723. PubMed ID: 22848092
[TBL] [Abstract][Full Text] [Related]
33. Valproic acid affected the survival and invasiveness of human glioma cells through diverse mechanisms.
Chen Y; Tsai YH; Tseng SH
J Neurooncol; 2012 Aug; 109(1):23-33. PubMed ID: 22528797
[TBL] [Abstract][Full Text] [Related]
34. Biologically targeted therapeutics in pediatric brain tumors.
Nageswara Rao AA; Scafidi J; Wells EM; Packer RJ
Pediatr Neurol; 2012 Apr; 46(4):203-11. PubMed ID: 22490764
[TBL] [Abstract][Full Text] [Related]
35. Suberoylanilide hydroxamic acid affects γH2AX expression in osteosarcoma, atypical teratoid rhabdoid tumor and normal tissue cell lines after irradiation.
Blattmann C; Oertel S; Thiemann M; Weber KJ; Schmezer P; Zelezny O; Lopez Perez R; Kulozik AE; Debus J; Ehemann V
Strahlenther Onkol; 2012 Feb; 188(2):168-76. PubMed ID: 22249335
[TBL] [Abstract][Full Text] [Related]
36. Valproic acid overcomes hypoxia-induced resistance to apoptosis.
Cipro Š; Hřebačková J; Hraběta J; Poljaková J; Eckschlager T
Oncol Rep; 2012 Apr; 27(4):1219-26. PubMed ID: 22159638
[TBL] [Abstract][Full Text] [Related]
37. Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells.
Knipstein JA; Birks DK; Donson AM; Alimova I; Foreman NK; Vibhakar R
Neuro Oncol; 2012 Feb; 14(2):175-83. PubMed ID: 22156471
[TBL] [Abstract][Full Text] [Related]
38. Combination of suberoylanilide hydroxamic acid with heavy ion therapy shows promising effects in infantile sarcoma cell lines.
Oertel S; Thiemann M; Richter K; Weber KJ; Huber PE; Perez RL; Brons S; Bischof M; Kulozik AE; Ehemann V; Debus J; Blattmann C
Radiat Oncol; 2011 Sep; 6():119. PubMed ID: 21933400
[TBL] [Abstract][Full Text] [Related]
39. Atypical teratoid/rhabdoid tumors in adults: a case report and treatment-focused review.
Shonka NA; Armstrong TS; Prabhu SS; Childress A; Choi S; Langford LA; Gilbert MR
J Clin Med Res; 2011 Apr; 3(2):85-92. PubMed ID: 21811535
[TBL] [Abstract][Full Text] [Related]
40. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
Bush ML; Oblinger J; Brendel V; Santarelli G; Huang J; Akhmametyeva EM; Burns SS; Wheeler J; Davis J; Yates CW; Chaudhury AR; Kulp S; Chen CS; Chang LS; Welling DB; Jacob A
Neuro Oncol; 2011 Sep; 13(9):983-99. PubMed ID: 21778190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
